Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study

Maria-Antonietta D'Agostino; Maarten Boers; Richard J Wakefield; Hilde Berner Hammer; Olivier Vittecoq; Georgios Filippou; Peter Balint; Ingrid Möller; Annamaria Iagnocco; Esperanza Naredo; Mikkel Østergaard; Corine Gaillez; Manuela Le Bars

doi:10.1136/rmdopen-2015-000237

Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study

Maria-Antonietta D'Agostino, Maarten Boers, Richard J Wakefield, Hilde Berner Hammer, Olivier Vittecoq, Georgios Filippou, Peter Balint, Ingrid Möller, Annamaria Iagnocco, Esperanza Naredo, Mikkel Østergaard, Corine Gaillez, Manuela Le Bars

Department of Clinical Medicine

39 Citations (Scopus)

224 Downloads (Pure)

Abstract

Objectives: To explore whether changes in a composite ( power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). Methods: Patients with RA who were methotrexate inadequate responders starting abatacept were evaluated. Individual joint PDUS scores were combined in the Global OMERACT-EULAR Synovitis Score (GLOESS) for metacarpophalangeal joints (MCPs) 2-5, all joints (22 paired) and a reduced (9 paired) joint set. The predictive value of changes in GLOESS at week 1-16 evaluations for clinical status and response (Disease Activity Score (DAS) 28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2; DAS28(CRP) ≥1.2 improvement) up to week 24, and correlations between DAS28 and GLOESS were assessed. Results: Eighty-nine patients completed the 24-week treatment period. Changes in GLOESS (MCPs 2-5) from weeks 1 to 16 were unable to predict DAS28 outcomes up to week 24. However, significant improvements in GLOESS (MCPs 2-5) were observed at week 12 in patients with DAS28 ≥1.2 improvement at week 24 versus those who did not achieve that clinical response. In patients achieving DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24, changes in GLOESS (22 and 9 paired joint sets) were greater in patients who already achieved DAS28 ≥1.2 at week 12 than in those who did not. No significant correlations were found between changes in DAS28 and GLOESS definitions at any time point. Conclusions: PDUS was not correlated with clinical status or response as measured by DAS28-derived criteria, and PDUS changes were not predictive of clinical outcome. The discrepancies require further exploration. Trial registration number: NCT00767325; Results.

Original language	English
Article number	e000237
Journal	RMD Open: Rheumatic & Musculoskeletal Diseases
Volume	2
Issue number	1
Number of pages	8
ISSN	2056-5933
DOIs	https://doi.org/10.1136/rmdopen-2015-000237
Publication status	Published - 2016

Access to Document

10.1136/rmdopen-2015-000237Licence: CC BY-NC

Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE studyFinal published version, 871 KBLicence: CC BY-NC

Cite this

D'Agostino, M-A., Boers, M., Wakefield, R. J., Hammer, H. B., Vittecoq, O., Filippou, G., Balint, P., Möller, I., Iagnocco, A., Naredo, E., Østergaard, M., Gaillez, C., & Le Bars, M. (2016). Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study. RMD Open: Rheumatic & Musculoskeletal Diseases, 2(1), [e000237]. https://doi.org/10.1136/rmdopen-2015-000237

Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept : Results from the APPRAISE study. / D'Agostino, Maria-Antonietta; Boers, Maarten; Wakefield, Richard J et al.

In: RMD Open: Rheumatic & Musculoskeletal Diseases, Vol. 2, No. 1, e000237, 2016.

Research output: Contribution to journal › Journal article › Research › peer-review

D'Agostino, M-A, Boers, M, Wakefield, RJ, Hammer, HB, Vittecoq, O, Filippou, G, Balint, P, Möller, I, Iagnocco, A, Naredo, E, Østergaard, M, Gaillez, C & Le Bars, M 2016, 'Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study', RMD Open: Rheumatic & Musculoskeletal Diseases, vol. 2, no. 1, e000237. https://doi.org/10.1136/rmdopen-2015-000237

@article{fdbad7effd1a4f80bfaa544d04e24e1c,

title = "Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study",

abstract = "Objectives: To explore whether changes in a composite ( power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). Methods: Patients with RA who were methotrexate inadequate responders starting abatacept were evaluated. Individual joint PDUS scores were combined in the Global OMERACT-EULAR Synovitis Score (GLOESS) for metacarpophalangeal joints (MCPs) 2-5, all joints (22 paired) and a reduced (9 paired) joint set. The predictive value of changes in GLOESS at week 1-16 evaluations for clinical status and response (Disease Activity Score (DAS) 28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2; DAS28(CRP) ≥1.2 improvement) up to week 24, and correlations between DAS28 and GLOESS were assessed. Results: Eighty-nine patients completed the 24-week treatment period. Changes in GLOESS (MCPs 2-5) from weeks 1 to 16 were unable to predict DAS28 outcomes up to week 24. However, significant improvements in GLOESS (MCPs 2-5) were observed at week 12 in patients with DAS28 ≥1.2 improvement at week 24 versus those who did not achieve that clinical response. In patients achieving DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24, changes in GLOESS (22 and 9 paired joint sets) were greater in patients who already achieved DAS28 ≥1.2 at week 12 than in those who did not. No significant correlations were found between changes in DAS28 and GLOESS definitions at any time point. Conclusions: PDUS was not correlated with clinical status or response as measured by DAS28-derived criteria, and PDUS changes were not predictive of clinical outcome. The discrepancies require further exploration. Trial registration number: NCT00767325; Results.",

author = "Maria-Antonietta D'Agostino and Maarten Boers and Wakefield, {Richard J} and Hammer, {Hilde Berner} and Olivier Vittecoq and Georgios Filippou and Peter Balint and Ingrid M{\"o}ller and Annamaria Iagnocco and Esperanza Naredo and Mikkel {\O}stergaard and Corine Gaillez and {Le Bars}, Manuela",

year = "2016",

doi = "10.1136/rmdopen-2015-000237",

language = "English",

volume = "2",

journal = "RMD Open",

issn = "2056-5933",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept

T2 - Results from the APPRAISE study

AU - D'Agostino, Maria-Antonietta

AU - Boers, Maarten

AU - Wakefield, Richard J

AU - Hammer, Hilde Berner

AU - Vittecoq, Olivier

AU - Filippou, Georgios

AU - Balint, Peter

AU - Möller, Ingrid

AU - Iagnocco, Annamaria

AU - Naredo, Esperanza

AU - Østergaard, Mikkel

AU - Gaillez, Corine

AU - Le Bars, Manuela

PY - 2016

Y1 - 2016

N2 - Objectives: To explore whether changes in a composite ( power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). Methods: Patients with RA who were methotrexate inadequate responders starting abatacept were evaluated. Individual joint PDUS scores were combined in the Global OMERACT-EULAR Synovitis Score (GLOESS) for metacarpophalangeal joints (MCPs) 2-5, all joints (22 paired) and a reduced (9 paired) joint set. The predictive value of changes in GLOESS at week 1-16 evaluations for clinical status and response (Disease Activity Score (DAS) 28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2; DAS28(CRP) ≥1.2 improvement) up to week 24, and correlations between DAS28 and GLOESS were assessed. Results: Eighty-nine patients completed the 24-week treatment period. Changes in GLOESS (MCPs 2-5) from weeks 1 to 16 were unable to predict DAS28 outcomes up to week 24. However, significant improvements in GLOESS (MCPs 2-5) were observed at week 12 in patients with DAS28 ≥1.2 improvement at week 24 versus those who did not achieve that clinical response. In patients achieving DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24, changes in GLOESS (22 and 9 paired joint sets) were greater in patients who already achieved DAS28 ≥1.2 at week 12 than in those who did not. No significant correlations were found between changes in DAS28 and GLOESS definitions at any time point. Conclusions: PDUS was not correlated with clinical status or response as measured by DAS28-derived criteria, and PDUS changes were not predictive of clinical outcome. The discrepancies require further exploration. Trial registration number: NCT00767325; Results.

AB - Objectives: To explore whether changes in a composite ( power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). Methods: Patients with RA who were methotrexate inadequate responders starting abatacept were evaluated. Individual joint PDUS scores were combined in the Global OMERACT-EULAR Synovitis Score (GLOESS) for metacarpophalangeal joints (MCPs) 2-5, all joints (22 paired) and a reduced (9 paired) joint set. The predictive value of changes in GLOESS at week 1-16 evaluations for clinical status and response (Disease Activity Score (DAS) 28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2; DAS28(CRP) ≥1.2 improvement) up to week 24, and correlations between DAS28 and GLOESS were assessed. Results: Eighty-nine patients completed the 24-week treatment period. Changes in GLOESS (MCPs 2-5) from weeks 1 to 16 were unable to predict DAS28 outcomes up to week 24. However, significant improvements in GLOESS (MCPs 2-5) were observed at week 12 in patients with DAS28 ≥1.2 improvement at week 24 versus those who did not achieve that clinical response. In patients achieving DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24, changes in GLOESS (22 and 9 paired joint sets) were greater in patients who already achieved DAS28 ≥1.2 at week 12 than in those who did not. No significant correlations were found between changes in DAS28 and GLOESS definitions at any time point. Conclusions: PDUS was not correlated with clinical status or response as measured by DAS28-derived criteria, and PDUS changes were not predictive of clinical outcome. The discrepancies require further exploration. Trial registration number: NCT00767325; Results.

U2 - 10.1136/rmdopen-2015-000237

DO - 10.1136/rmdopen-2015-000237

M3 - Journal article

C2 - 27175297

AN - SCOPUS:84987962115

SN - 2056-5933

VL - 2

JO - RMD Open

JF - RMD Open

IS - 1

M1 - e000237

ER -

Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study

Abstract

Access to Document

Fingerprint

Cite this